Search Results - "Huober, J"

SA 11.4 Duration of endocrine therapy in early breast cancer by Huober, J.

Get full text

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study by Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B.V., Blohmer, J.-U., Grischke, E.-M., Furlanetto, J., Tesch, H., Hanusch, C., Engels, K., Rezai, M., Jackisch, C., Schmitt, W.D., von Minckwitz, G., Thomalla, J., Kümmel, S., Rautenberg, B., Fasching, P.A., Weber, K., Rhiem, K., Denkert, C., Schneeweiss, A.

“…Combining immune-checkpoint inhibitors with chemotherapy yielded an increased response rates in patients with metastatic triple-negative breast cancer (TNBC)…”
Get full text

Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response by Loibl, S., Schneeweiss, A., Huober, J., Braun, M., Rey, J., Blohmer, J.-U., Furlanetto, J., Zahm, D.-M., Hanusch, C., Thomalla, J., Jackisch, C., Staib, P., Link, T., Rhiem, K., Solbach, C., Fasching, P.A., Nekljudova, V., Denkert, C., Untch, M.

“…Addition of immune checkpoint inhibitors to neoadjuvant chemotherapy (NACT) is a promising strategy in early breast cancer, but the optimal duration of therapy…”
Get full text

Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial by Geyer, C.E., Sikov, W.M., Huober, J., Rugo, H.S., Wolmark, N., O’Shaughnessy, J., Maag, D., Untch, M., Golshan, M., Lorenzo, J. Ponce, Metzger, O., Dunbar, M., Symmans, W.F., Rastogi, P., Sohn, J.H., Young, R., Wright, G.S., Harkness, C., McIntyre, K., Yardley, D., Loibl, S.

“…Primary analyses of the phase III BrighTNess trial showed addition of carboplatin with/without veliparib to neoadjuvant chemotherapy significantly improved…”
Get full text

Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA by Krop, I.E., Lin, N.U., Blackwell, K., Guardino, E., Huober, J., Lu, M., Miles, D., Samant, M., Welslau, M., Diéras, V.

“…We characterized the incidence of central nervous system (CNS) metastases after treatment with trastuzumab emtansine (T-DM1) versus capecitabine–lapatinib…”
Get full text

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 by Curigliano, G, Burstein, H.J., Winer, E.P., Gnant, M., Dubsky, P., Loibl, S., Colleoni, M., Regan, M.M., Piccart-Gebhart, M., Senn, H.-J., Thürlimann, B., André, F., Baselga, J., Bergh, J., Bonnefoi, H., Brucker, S.Y., Cardoso, F., Carey, L., Ciruelos, E., Cuzick, J., Denkert, C., Di Leo, A., Ejlertsen, B., Francis, P., Galimberti, V., Garber, J., Gulluoglu, B., Goodwin, P., Harbeck, N., Hayes, D.F., Huang, C.-S., Huober, J., Khaled, H., Jassem, J., Jiang, Z., Karlsson, P., Morrow, M., Orecchia, R., Osborne, K.C., Pagani, O., Partridge, A.H., Pritchard, K., Ro, J., Rutgers, E.J.T., Sedlmayer, F., Semiglazov, V., Shao, Z., Smith, I., Toi, M., Tutt, A., Viale, G., Watanabe, T., Whelan, T.J., Xu, B.

“…The 15th St. Gallen International Breast Cancer Conference 2017 in Vienna, Austria reviewed substantial new evidence on loco-regional and systemic therapies…”
Get full text

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study) by Fasching, P.A., Link, T., Hauke, J., Seither, F., Jackisch, C., Klare, P., Schmatloch, S., Hanusch, C., Huober, J., Stefek, A., Seiler, S., Schmitt, W.D., Uleer, C., Doering, G., Rhiem, K., Schneeweiss, A., Engels, K., Denkert, C., Schmutzler, R.K., Hahnen, E., Untch, M., Burchardi, N., Blohmer, J.-U., Loibl, S.

“…The efficacy and toxicity of olaparib as combination therapy in early breast cancer (BC) patients with homologous recombinant deficiency (HRD) [score high…”
Get full text

Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial by Denkert, C., Loibl, S., Müller, B.M., Eidtmann, H., Schmitt, W.D., Eiermann, W., Gerber, B., Tesch, H., Hilfrich, J., Huober, J., Fehm, T., Barinoff, J., Jackisch, C., Prinzler, J., Rüdiger, T., Erbstößer, E., Blohmer, J.U., Budczies, J., Mehta, K.M., von Minckwitz, G.

“…The proliferation marker Ki67 has been suggested as a promising cancer biomarker. As Ki67 needs an exact quantification, this marker is a prototype of a new…”
Get full text

Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo by Karn, T., Denkert, C., Weber, K.E., Holtrich, U., Hanusch, C., Sinn, B.V., Higgs, B.W., Jank, P., Sinn, H.P., Huober, J., Becker, C., Blohmer, J.-U., Marmé, F., Schmitt, W.D., Wu, S., van Mackelenbergh, M., Müller, V., Schem, C., Stickeler, E., Fasching, P.A., Jackisch, C., Untch, M., Schneeweiss, A., Loibl, S.

“…The predictive value of tumor mutational burden (TMB), alone or in combination with an immune gene expression profile (GEP), for response to neoadjuvant…”
Get full text

Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy by Lindner, J.L., Loibl, S., Denkert, C., Ataseven, B., Fasching, P.A., Pfitzner, B.M., Gerber, B., Gade, S., Darb-Esfahani, S., Sinn, B.V., Huober, J., Engels, K., Tesch, H., Karn, T., Pommerenke, F., Liedtke, C., Untch, M., Müller, V., Rack, B., Schem, C., von Minckwitz, G.

“…Secreted protein acidic and rich in cysteine (SPARC) has been suggested as a new biomarker and therapeutic target in breast cancer, as well as other tumor…”
Get full text

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44) by GERBER, B, LOIBL, S, KREIENBERG, R, SOLBACH, C, JACKISCH, C, KUNZ, G, BLOHMER, J. U, HUOBER, J, HAUSCHILD, M, NEKLJUDOVA, V, UNTCH, M, VON MINCKWITZ, G, EIDTMANN, H, REZAI, M, FASCHING, P. A, TESCH, H, EGGEMANN, H, SCHRADER, I, KITTEL, K, HANUSCH, C

“…We evaluated the pathological complete response (pCR) rate after neoadjuvant epirubicin, (E) cyclophosphamide (C) and docetaxel containing chemotherapy with…”
Get full text

Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3 by Goetz, M P, Toi, M, Huober, J, Sohn, J, Trédan, O, Park, I H, Campone, M, Chen, S-C, Manso, L M, Paluch-Shimon, S, Freedman, O C, O'Shaughnessy, J, Pivot, X, Tolaney, S M, Hurvitz, S A, Llombart-Cussac, A, André, V, Saha, A, van Hal, G, Shahir, A, Iwata, H, Johnston, S R D

“…In MONARCH 2, the addition of abemaciclib to fulvestrant significantly improved both progression-free survival (PFS) and overall survival (OS) in patients with…”
Get more information

Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials by Huober, J., Gelber, S., Goldhirsch, A., Coates, A.S., Viale, G., Öhlschlegel, C., Price, K.N., Gelber, R.D., Regan, M.M., Thürlimann, B.

“…To evaluate whether medullary breast cancer has a better prognosis compared with invasive ductal tumors. Among 12 409 patients, 127 were recorded as invasive…”
Get full text

Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40—GeparQuattro) by von Minckwitz, G., Rezai, M., Fasching, P.A., Huober, J., Tesch, H., Bauerfeind, I., Hilfrich, J., Eidtmann, H., Gerber, B., Hanusch, C., Blohmer, J.U., Costa, S.D., Jackisch, C., Paepke, S., Schneeweiss, A., Kümmel, S., Denkert, C., Mehta, K., Loibl, S., Untch, M.

“…The GeparQuattro study showed that adding capecitabine or prolonging the duration of anthracycline-taxane-based neoadjuvant chemotherapy from 24 to 36 weeks…”
Get full text

VP6-2021: IMpassion050: A phase III study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy (neoadj A + PH + CT) in high-risk, HER2-positive early breast cancer (EBC) by Huober, J., Barrios, C.H., Niikura, N., Jarzab, M., Chang, Y-C., Huggins-Puhalla, S.L., Graupner, V., Eiger, D., Henschel, V., Gochitashvili, N., Lambertini, C., Restuccia, E., Zhang, H.

Get full text

Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – Results of the eLEcTRA trial by Huober, J, Fasching, P.A, Barsoum, M, Petruzelka, L, Wallwiener, D, Thomssen, C, Reimer, T, Paepke, S, Azim, H.A, Ragosch, V, Kubista, E, Baumgärtner, A.K, Beckmann, M.W, May, C, Nimmrich, I, Harbeck, N

“…Abstract The eLEcTRA trial compared efficacy and safety of letrozole combined with trastuzumab to letrozole alone in patients with HER2 and hormone receptor…”
Get full text

Corrigendum to “A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study”: [Annals of Oncology (2019), volume 30:1279-1288] by Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B.V., Blohmer, J.-U., Grischke, E.-M., Furlanetto, J., Tesch, H., Hanusch, C., Engels, K., Rezai, M., Jackisch, C., Schmitt, W.D., von Minckwitz, G., Thomalla, J., Kümmel, S., Rautenberg, B., Fasching, P.A., Weber, K., Rhiem, K., Denkert, C., Schneeweiss, A.

Get full text

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression by Nitz, U., Gluz, O., Huober, J., Kreipe, H.H., Kates, R.E., Hartmann, A., Erber, R., Scholz, M., Lisboa, B., Mohrmann, S., Möbus, V., Augustin, D., Hoffmann, G., Weiss, E., Böhmer, S., Kreienberg, R., Du Bois, A., Sattler, D., Thomssen, C., Kiechle, M., Jänicke, F., Wallwiener, D., Harbeck, N., Kuhn, W.

“…Taxane-based adjuvant chemotherapy is standard in node-positive (N+) early breast cancer (BC). The magnitude of benefit in intermediate-risk N+ early BC is…”
Get full text

Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program by Müller, V., Banys-Paluchowski, M., Friedl, T.W.P., Fasching, P.A., Schneeweiss, A., Hartkopf, A., Wallwiener, D., Rack, B., Meier-Stiegen, F., Huober, J., Rübner, M., Hoffmann, O., Müller, L., Janni, W., Wimberger, P., Jäger, B., Pantel, K., Riethdorf, S., Harbeck, N., Fehm, T.

“…Circulating tumor cells (CTCs) have been reported to predict clinical outcome in metastatic breast cancer (MBC). Biology of CTCs may differ from that of the…”
Get full text

Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment? by Joerger, M., Thürlimann, B., Huober, J.

“…Adjuvant treatment of early-stage breast cancer with combined trastuzumab and chemotherapy has become standard in patients with HER2-positive tumors and a…”
Get full text